|Bid||0.0070 x 59129200|
|Ask||0.0070 x 100647600|
|Day's range||0.0060 - 0.0070|
|52-week range||0.0030 - 0.0110|
|Beta (5Y monthly)||0.56|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Data from a preclinical study shows that treatment with Alterity's (ATHE) lead candidate improved motor performance and general function in monkeys with experimentally-induced Parkinson's disease.
Key Insights Alterity Therapeutics' Annual General Meeting to take place on 28th of November CEO David Stamler's total...
Here is how Vir Biotechnology, Inc. (VIR) and Prana Biotechnology Ltd (ATHE) have performed compared to their sector so far this year.